EuroEyes International Eye Clinic Limited (1846) Earnings Call Transcripts

EuroEyes International Eye Clinic Limited's Latest Earnings Call - April 1, 2026

In the fiscal year 2025, EuroEyes International Eye Clinic Limited reported a revenue of HKD 800 million, reflecting an 11% growth year-over-year, driven primarily by the presbyopia segment. However, net profit decreased by 33% due to costs associated with the acquisition of clinics in Switzerland and foreign exchange losses. Management expects the Swiss operations to achieve EBITDA breakeven by Q2 2026, signaling a potential turnaround that could positively impact future earnings.

Reported metrics

Guidance from management

Management expects the Swiss operations to achieve EBITDA breakeven by Q2 2026 and anticipates continued growth in the presbyopia segment, with a revenue CAGR target of low to mid-10s over the next decade.

What management said

Yes. I think we have some questions. Thank you, Dr. Jorgensen. I don't know who will lead off, maybe we take them in the turn that they were presented. I think first question, I'm aware that some were submitted before.

Yes. I think we will be issuing in the context of the fact that this is a very substantial acquisition of ESA. We are required to produce a circular, and that will contain detailed disclosures also on the financing. So I think what I -- my comments just now are what I'm prepared to say at this stage.

What analysts pressed on

Analysts expressed concerns regarding the impact of foreign exchange losses on net profit and the sustainability of growth in light of rising marketing expenses. There is also apprehension about the integration of recent acquisitions and their contribution to overall profitability.

Main topics on the call

• Acquisition Strategy — EuroEyes successfully acquired clinics in Switzerland and is in the process of acquiring FYEO in the Netherlands, which is expected to contribute EUR 64 million in revenue. CEO Jorgensen stated, "this will put EuroEyes i...
• Revenue Growth — The company reported a revenue increase of 11% year-over-year, reaching HKD 800 million. Excluding the Swiss acquisition, organic revenue growth was 10%, indicating strong core business performance.
• EBITDA Performance — EBITDA grew by 11%, but only 6% when including the Swiss acquisition, which is currently in a turnaround phase. CFO Bracklo noted, "we expect this operation to reach EBITDA breakeven by the second quarter of 2026," sugge...
• Market Expansion Potential — Management emphasized significant growth opportunities in presbyopia treatment, particularly in underpenetrated markets like the U.S. and China. Jorgensen remarked, "we see that as the biggest opportunity" for future gro...

Read the full EuroEyes International Eye Clinic Limited transcript (April 1, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 8 EuroEyes International Eye Clinic Limited earnings call transcripts on record, spanning March 17, 2021 to April 1, 2026. Based on this history, EuroEyes International Eye Clinic Limited reports annually. The most recent call on file is dated April 1, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

1846

Exchange

SEHK

Country

HK

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

8

First call

March 17, 2021

Most recent

April 1, 2026

Reporting cadence

annually